Taniborbactam

Taniborbactam
Clinical data
Other namesVNRX-5133, VNRX5133
Legal status
Legal status
  • Investigational
Identifiers
  • (3R)-3-[[2-[4-(2-Aminoethylamino)cyclohexyl]acetyl]amino]-2-hydroxy-3,4-dihydro-1,2-benzoxaborinine-8-carboxylic acid
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC19H28BN3O5
Molar mass389.26 g·mol−1
3D model (JSmol)
  • O=C(O)C1=CC=CC2=C1OB(O)[C@@H](NC(C[C@@H]3CC[C@@H](NCCN)CC3)=O)C2
  • InChI=InChI=1S/C19H28BN3O5/c21-8-9-22-14-6-4-12(5-7-14)10-17(24)23-16-11-13-2-1-3-15(19(25)26)18(13)28-20(16)27/h1-3,12,14,16,22,27H,4-11,21H2,(H,23,24)(H,25,26)/t12?,14?,16-/m0/s1
  • Key:PFZUWUXKQPRWAL-PXCJXSSVSA-N

Taniborbactam (development code VNRX-5133) is a pharmaceutical drug that acts as a β-lactamase inhibitor.[1] It inhibits the function of bacterial β-lactamases which impart resistance to β-lactam antibiotics. However, unlike other β-lactamase inhibitors that are used as pharmaceuticals, taniborbactam is effective against enzymes of the New Delhi metallo-beta-lactamase 1 group which are the most frequently identified sources of acquired antibiotic resistance worldwide.[2]

Taniborbactam, in combination with cefepime, is in clinical trials for the treatment of bacterial infections, including urinary tract infection and pyelonephritis.[3][4]

References

  1. ^ Liu B, Trout RE, Chu GH, McGarry D, Jackson RW, Hamrick JC, et al. (March 2020). "Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-β-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections". Journal of Medicinal Chemistry. 63 (6): 2789–2801. doi:10.1021/acs.jmedchem.9b01518. PMC 7104248. PMID 31765155.
  2. ^ Le Terrier C, Gruenig V, Fournier C, Nordmann P, Poirel L (April 2023). "NDM-9 resistance to taniborbactam". The Lancet. Infectious Diseases. 23 (4): 401–402. doi:10.1016/S1473-3099(23)00069-5. PMID 36796395.
  3. ^ Wagenlehner FM, Gasink LB, McGovern PC, Moeck G, McLeroth P, Dorr M, et al. (February 2024). "Cefepime-Taniborbactam in Complicated Urinary Tract Infection". The New England Journal of Medicine. 390 (7): 611–622. doi:10.1056/NEJMoa2304748. PMID 38354140.
  4. ^ "Cefepime/taniborbactam - VenatoRx Pharmaceuticals". AdisInsight. Springer Nature Switzerland AG.
Stub icon

This antiinfective drug article is a stub. You can help Wikipedia by adding missing information.

Content Disclaimer

Informasi ini disarikan dari Wikipedia dan disajikan kembali untuk tujuan edukasi. Konten tersedia di bawah lisensi CC BY-SA 3.0. Kami tidak bertanggung jawab atas ketidakakuratan data yang bersumber dari kontribusi publik tersebut.

  1. The information displayed on this website is sourced in part or in whole from Wikipedia and has been adapted for the purpose of restating it. We strive to provide accurate and relevant information, however:
  2. There is no guarantee of absolute accuracy. Wikipedia is an open, collaborative project that can be edited by anyone, so information is subject to change.
  3. It is not intended to constitute professional advice. The content displayed is for informational and educational purposes only. For important decisions (e.g., medical, legal, or financial), please consult a professional.
  4. Content copyright. Wikipedia is licensed under the Creative Commons Attribution-ShareAlike License (CC BY-SA). This means that content may be reused with appropriate attribution and shared under a similar license.
  5. Responsible use. Any risk arising from the use of information from this website is entirely the responsibility of the user.